The spectrum of MYH9-associated nephropathy

Clinical Journal of the American Society of Nephrology

Volumn 5, Issue 6, 2010, Pages 1107-1113

  Bostrom, Meredith A ^a   Freedman, Barry I ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYOSIN HEAVY CHAIN; MYOSIN HEAVY CHAIN 9; UNCLASSIFIED DRUG; MOLECULAR MOTOR; MYH9 PROTEIN, HUMAN;

AFRICAN AMERICAN; ETHNICITY; EUROPEAN AMERICAN; GENETIC VARIABILITY; HUMAN; INCIDENCE; KIDNEY DISEASE; RISK FACTOR; SHORT SURVEY; BIOPSY; CAUCASIAN; CHRONIC DISEASE; DISEASE COURSE; ETHNOLOGY; GENETIC PREDISPOSITION; GENETICS; HYPERTENSION; KIDNEY; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; RISK ASSESSMENT;

AFRICAN AMERICANS; BIOPSY; CHRONIC DISEASE; DISEASE PROGRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION; KIDNEY; KIDNEY DISEASES; MOLECULAR MOTOR PROTEINS; MYOSIN HEAVY CHAINS; PHENOTYPE; RISK ASSESSMENT; RISK FACTORS;

EID: 77953309575     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.08721209     Document Type: Short Survey

References (52)

1. Freedman BI, Iskandar SS, Appel RG: The link between hypertension and nephrosclerosis. Am J Kidney Dis 25: 207-221, 1995
2. Freedman BI, Sedor JR: Hypertension-associated kidney disease: Perhaps no more. J Am Soc Nephrol 19: 2047-2051, 2008
3. Zarif L, Covic A, Iyengar S, Sehgal AR, Sedor JR, Schelling JR: Inaccuracy of clinical phenotyping parameters for hypertensive nephrosclerosis. Nephrol Dial Transplant 15: 1801-1807, 2000
4. US Renal Data System: USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2008
5. Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, Schneider KA: Prognostic value of serum creatinine and effect of treatment of hypertension on renal function: Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 13: I80-I93, 1989
6. Walker WG, Neaton JD, Cutler JA, Neuwirth R, Cohen JD: Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial: Racial and treatment effects. The MRFIT Research Group. JAMA 268: 3085-3091, 1992
7. Perneger TV, Whelton PK, Klag MJ, Rossiter KA: Diagnosis of hypertensive end-stage renal disease: Effect of patient's race. Am J Epidemiol 141: 10-15, 1995
8. Schlessinger SD, Tankersley MR, Curtis JJ: Clinical documentation of end-stage renal disease due to hypertension. Am J Kidney Dis 23: 655-660, 1994 (Pubitemid 24138418)
9. Freedman BI, Iskander SS, Buckalew VM Jr, Burkart JM, Appel RG: Renal biopsy findings in presumed hypertensive nephrosclerosis. Am J Nephrol 14: 90-94, 1994
10. Fogo A, Breyer JA, Smith MC, Cleveland WH, Agodoa L, Kirk KA, Glassock R: Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: A report from the African American Study of Kidney Disease (AASK) Trial. AASK Pilot Study Investigators. Kidney Int 51: 244-252, 1997
11. Marcantoni C, Ma LJ, Federspiel C, Fogo AB: Hypertensive nephrosclerosis in African Americans versus Caucasians. Kidney Int 62: 172-180, 2002
12. Bleyer AJ, Chen R, D'Agostino RB Jr, Appel RG: Clinical correlates of hypertensive end-stage renal disease. Am J Kidney Dis 31: 28-34, 1998 (Pubitemid 28116679)
13. Bianchi S, Bigazzi R, Caiazza A, Campese VM: A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 41: 565-570, 2003
14. Phisitkul K, Hegazy K, Chuahirun T, Hudson C, Simoni J, Rajab H, Wesson DE: Continued smoking exacerbates but cessation ameliorates progression of early type 2 diabetic nephropathy. Am J Med Sci 335: 284-291, 2008
15. Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK, Treating to New Targets Investigators: Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: The Treating to New Targets (TNT) Study. Clinical J Am Soc Nephrol 2: 1131-1139, 2007
16. Appel LJ, Wright JT Jr, Greene T, Kusek JW, Lewis JB, Wang X, Lipkowitz MS, Norris KC, Bakris GL, Rahman M, Contreras G, Rostand SG, Kopple JD, Gabbai FB, Schulman GI, Gassman JJ, Charleston J, Agodoa LY, African American Study of Kidney Disease and Hypertension Collaborative Research Group: Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med 168: 832-839, 2008
17. McClellan W, Tuttle E, Issa A: Racial differences in the incidence of hypertensive end-stage renal disease (ESRD) are not entirely explained by differences in the prevalence of hypertension. Am J Kidney Dis 12: 285-290, 1988
18. Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW, Oleksyk T, McKenzie LM, Kajiyama H, Ahuja TS, Berns JS, Briggs W, Cho ME, Dart RA, Kimmel PL, Korbet SM, Michel DM, Mokrzycki MH, Schelling JR, Simon E, Trachtman H, Vlahov D, Winkler CA: MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 40: 1175-1184, 2008
19. Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M, Coresh J, Patterson N, Tandon A, Powe NR, Fink NE, Sadler JH, Weir MR, Abboud HE, Adler SG, Divers J, Iyengar SK, Freedman BI, Kimmel PL, Knowler WC, Kohn OF, Kramp K, Leehey DJ, Nicholas SB, Pahl MV, Schelling JR, Sedor JR, Thornley-Brown D, Winkler CA, Smith MW, Parekh RS: MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 40: 1185-1192, 2008
20. Freedman BI, Hicks PJ, Bostrom MA, Cunningham ME, Liu Y, Divers J, Kopp JB, Winkler CA, Nelson GW, Langefeld CD, Bowden DW: Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans. Kidney Int 75: 736-745, 2009
21. Freedman BI, Tuttle AB, Spray BJ: Familial predisposition to nephropathy in African-Americans with non-insulin-dependent diabetes mellitus. Am J Kidney Dis 25: 710-713, 1995
22. Ferguson R, Grim CE, Opgenorth TJ: A familial risk of chronic renal failure among blacks on dialysis? J Clin Epidemiol 41: 1189-1196, 1988
23. Seaquist ER, Goetz FC, Rich S, Barbosa J: Familial clustering of diabetic kidney disease: Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 320: 1161-1165, 1989 (Pubitemid 19124296)
24. Freedman BI, Spray BJ, Tuttle AB, Buckalew VM Jr: The familial risk of end-stage renal disease in African Americans. Am J Kidney Dis 21: 387-393, 1993 (Pubitemid 23132903)
25. Freedman BI, Wilson CH, Spray BJ, Tuttle AB, Olorenshaw IM, Kammer GM: Familial clustering of end-stage renal disease in blacks with lupus nephritis. Am J Kidney Dis 29: 729-732, 1997 (Pubitemid 27209675)
26. Freedman BI, Soucie JM, Stone SM, Pegram S: Familial clustering of end-stage renal disease in blacks with HIV-associated nephropathy. Am J Kidney Dis 34: 254-258, 1999
27. Bergman S, Key BO, Kirk KA, Warnock DG, Rostant SG: Kidney disease in the first-degree relatives of African-Americans with hypertensive end-stage renal disease. Am J Kidney Dis 27: 341-346, 1996 (Pubitemid 26075842)
28. Lei HH, Perneger TV, Klag MJ, Whelton PK, Coresh J: Familial aggregation of renal disease in a population-based case-control study. J Am Soc Nephrol 9: 1270-1276, 1998 (Pubitemid 28283891)
29. Freedman BI, Volkova NV, Satko SG, Krisher J, Jurkovitz C, Soucie JM, McClellan WM: Population-based screening for family history of end-stage renal disease among incident dialysis patients. Am J Nephrol 25: 529-535, 2005
30. Song EY, McClellan WM, McClellan A, Rajyalakshmi G, Hadley AC, Krisher J, Clay M, Freedman BI: Effect of community characteristics on familial clustering of end-stage renal disease. Am J Nephrol 30: 499-504, 2009
31. Freedman BI: End-stage renal failure in African Americans: Insights in kidney disease susceptibility. Nephrol Dial Transplant 17: 198-200, 2002 (Pubitemid 34157127)
32. Smith MW, Patterson N, Lautenberger JA, Truelove AL, McDonald GJ, Waliszewska A, Kessing BD, Malasky MJ, Scafe C, Le E, De Jager PL, Mignault AA, Yi Z, De The G, Essex M, Sankale JL, Moore JH, Poku K, Phair JP, Goedert JJ, Vlahov D, Williams SM, Tishkoff SA, Winkler CA, De La Vega FM, Woodage T, Sninsky JJ, Hafler DA, Altshuler D, Gilbert DA, O'Brien SJ, Reich D: A high-density admixture map for disease gene discovery in African Americans. Am J Hum Genet 74: 1001-1013, 2004
33. McCarthy MI: What will genome-wide association studies mean to the clinical endocrinologist? J Clin Endocrinol Metab 94: 2245-2246, 2009
34. Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, Helgason A, Stefansson H, Emilsson V, Helgadottir A, Styrkarsdottir U, Magnusson KP, Walters GB, Palsdottir E, Jonsdottir T, Gudmundsdottir T, Gylfason A, Saemundsdottir J, Wilensky RL, Reilly MP, Rader DJ, Bagger Y, Christiansen C, Gudnason V, Sigurdsson G, Thorsteinsdottir U, Gulcher JR, Kong A, Stefansson K: Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 38: 320-323, 2006
35. Marini M, Bruschi M, Pecci A, Romagnoli R, Musante L, Candiano G, Ghiggeri GM, Balduini C, Seri M, Ravazzolo R: Non-muscle myosin heavy chain IIA and IIB interact and co-localize in living cells: Relevance for MYH9-related disease. Int J Mol Med 17: 729-736, 2006
36. Arrondel C, Vodovar N, Knebelmann B, Grunfeld JP, Gubler MC, Antignac C, Heidet L: Expression of the nonmuscle myosin heavy chain IIA in the human kidney and screening for MYH9 mutations in Epstein and Fechtner syndromes. J Am Soc Nephrol 13: 65-74, 2002 (Pubitemid 34042012)
37. Heath KE, Campos-Barros A, Toren A, Rozenfeld-Granot G, Carlsson LE, Savige J, Denison JC, Gregory MC, White JG, Barker DF, Greinacher A, Epstein CJ, Glucksman MJ, Martignetti JA: Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes. Am J Hum Genet 69: 1033-1045, 2001
38. Seri M, Cusano R, Gangarossa S, Caridi G, Bordo D, Lo NC, Ghiggeri GM, Ravazzolo R, Savino M, Del Vecchio M, d'Apolito M, Iolascon A, Zelante LL, Savoia A, Balduini CL, Noris P, Magrini U, Belletti S, Heath KE, Babcock M, Glucksman MJ, Aliprandis E, Bizzaro N, Desnick RJ, Martignetti JA: Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Hegglin/Fechtner Syndrome Consortium. Nat Genet 26: 103-105, 2000
39. Papeta N, Chan KT, Prakash S, Martino J, Kiryluk K, Ballard D, Bruggeman LA, Frankel R, Zheng Z, Klotman PE, Zhao H, D'Agati VD, Lifton RP, Gharavi AG: Susceptibility loci for murine HIV-associated nephropathy encode trans-regulators of podocyte gene expression. J Clin Invest 119: 1178-1188, 2009
40. Tanawattanacharoen S, Falk RJ, Jennette JC, Kopp JB: Parvovirus B19 DNA in kidney tissue of patients with focal segmental glomerulosclerosis. Am J Kidney Dis 35: 1166-1174, 2000 (Pubitemid 30354422)
41. Celik B, Randhawa PS: Glomerular changes in BK virus nephropathy. Hum Pathol 35: 367-370, 2004
42. Boute N, Gribouval O, Roselli S, Benessy F, Lee H, Fuchshuber A, Dahan K, Gubler MC, Niaudet P, Antignac C: NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet 24: 349-354, 2000
43. Kaplan JM, Kim SH, North KN, Rennke H, Correia LA, Tong HQ, Mathis BJ, Rodriguez-Perez JC, Allen PG, Beggs AH, Pollak MR: Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet 24: 251-256, 2000
44. Winn MP, Conlon PJ, Lynn KL, Farrington MK, Creazzo T, Hawkins AF, Daskalakis N, Kwan SY, Ebersviller S, Burchette JL, Pericak-Vance MA, Howell DN, Vance JM, Rosenberg PB: A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 308: 1801-1804, 2005
45. Freedman BI, Kopp JB, Winkler CA, Nelson GW, Rao DC, Eckfeldt JH, Leppert MF, Hicks PJ, Divers J, Langefeld CD, Hunt SC: Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are associated with albuminuria in hypertensive African Americans: The HyperGEN study. Am J Nephrol 29: 626-632, 2009
46. Lipkowitz MS, Iyengar S, Molineros J, Langefeld CD, Comeau ME, Klotman PE, Bowden DW, Freedman RG, Khitrov G, Zhang W, Kao WH, Parekh RS, Choi M, Kopp JB, Winkler CA, Nelson G, Freedman BI, Bottinger EP, AASK Investigators: Association analysis of the non-muscle myosin heavy chain 9 gene (MYH9) in hypertensive nephropathy: African American Study of Kidney Disease and Hypertension (AASK) [Abstract]. J Am Soc Nephrol 20: 56A, 2009
47. Barisoni L, Kriz W, Mundel P, D'Agati V: The dysregulated podocyte phenotype: A novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 10: 51-61, 1999 (Pubitemid 29034942)
48. Reeves-Daniel AM, Iskandar SS, Bowden DW, Bostrom MA, Hicks PJ, Comeau ME, Langefeld CD, Freedman BI: Is collapsing C1q nephropathy another MYH9-associated kidney disease? A case report. Am J Kidney Dis January 27, 2010 [epub ahead of print]
49. Freedman BI, Hicks PJ, Bostrom MA, Comeau ME, Divers J, Bleyer AJ, Kopp JB, Winkler CA, Nelson GW, Langefeld CD, Bowden DW: Non-muscle myosin heavy chain 9 gene MYH9 associations in African Americans with clinically diagnosed type 2 diabetes mellitus-associated ESRD. Nephrol Dial Transplant 24: 3366-3371, 2009
50. Katznelson S, Gjertson DW, Cecka JM: The effect of race and ethnicity on kidney allograft outcome. Clin Transpl 379-394, 1995
51. Callender CO, Cherikh WS, Miles PV, Hermesch A, Maddox G, Nash J, Hernandez A, Burston B: Blacks as donors for transplantation: Suboptimal outcomes overcome by transplantation into other minorities. Transplant Proc 40: 995-1000, 2008
52. Barrett JC, Fry B, Maller J, Daly MJ: Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265, 2005